If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
The offer price is approximately 4.32% below the closing price of the Merck common stock on November 11, 2024
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer
HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
He did Master’s of Pharmacy (Pharmaceutical Technology, Formulations) from National Institute of Pharmaceutical Education and Research, Mohali and Bachelor of Pharmacy from Osmania University
Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters
Opinion granted based on positive overall survival results from the IND.227/KEYNOTE-483 trial
Donation drive in São Paulo aims to support 250 young women’s health and environmental responsibility
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
